Live feed08:05:00·45dNEWSReleasevia QuantisnowProtagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque PsoriasisByQuantisnow·Wall Street's wire, on your screen.PTGX· Protagonist Therapeutics Inc.Health Care
